20th Annual Conference on Vaccine Research (2017)

Detailed Agenda

0 results found.

Type here to filter the list

Monday, April 24, 2017
7:30 AM - 8:30 AM

Continental Breakfast
7:30 AM - 8:30 AM

Continental Breakfast

Favorite
8:30 AM - 9:30 AM

Opening Keynote: Greatest Vaccinology Discoveries of the Last Decade and Future Predictions
8:30 AM - 9:30 AM

Opening Keynote: Greatest Vaccinology Discoveries of the Last Decade and Future Predictions

Favorite

Stanley A. Plotkin, MD – University of Pennsylvania and Vaxconsult ### 141564###Keynote Speaker @@@ Walter A. Orenstein, MD – Emory University ### 79257###Moderator
9:30 AM - 11:00 AM

Symposium 1: Challenges Implementing the World's First Licensed Dengue Vaccine
9:40 AM - 9:55 AM

S1-1 - Long Road to Preventing Dengue Disease by Vaccination, and Future Prospects

Favorite

Duane J. Gubler, ScD, MS – Duke National University of Singapore Medical School ### 307021###Presenter
9:55 AM - 10:10 AM

S1-2 - Biology of Antibody-enhanced Dengue Disease: Evidence of Increased Risk After CYD-TDV Vaccination

Favorite

Scott B. Halstead, MD – International Vaccine Institute ### 78363###Presenter
10:10 AM - 10:25 AM

S1-3 - Optimal use of the First Licensed Dengue Vaccine: Balancing Benefit against Potential Risks

Favorite

Neil M. Ferguson, PhD – Imperial College London ### 307023###Presenter
10:25 AM - 10:40 AM

S1-4 - Maximizing Benefit and Minimizing Risk for the World’s First Licensed Dengue Vaccine: CYD-TDV

Favorite

Timothy P. Endy, MD, MPH – State University of New York, Upstate Medical University ### 79041###Presenter
11:00 AM - 11:30 AM

Coffee Break
11:00 AM - 11:30 AM

Coffee Break

Favorite
11:30 AM - 1:00 PM

Symposium 2: Development and Approval Pathways of Vaccines for the Prevention of Emerging Infectious Diseases
11:40 AM - 11:55 AM

S2-1 - Epidemiology, Disease Burden, and Population Targets For Zika Vaccine

Favorite

Marcos A. Espinal, MD, DrPH, MPH – Pan American Health Organization ### 316811###Presenter
11:55 AM - 12:10 PM

S2-2 - BARDA Perspective About Challenges and Opportunities in Developing EID Vaccines

Favorite

Ruben O. Donis, PhD – Biomedical Advanced Research and Development Authority (BARDA)
Office of the Assistant Secretary for Preparedness and Response (ASPR)
US Department of Health and Human Services ### 372170###Presenter
12:10 PM - 12:25 PM

S2-3 - Development and Approval Pathways for Vaccines to Prevent Emerging Infectious Diseases: FDA Regulatory Perspective

Favorite

Marion F. Gruber, PhD – US Food and Drug Administration ### 78362###Presenter
12:25 PM - 12:40 PM

S2-4 - Rapid Development of Candidate Zika Vaccines

Favorite

Barney S. Graham, MD, PhD – National Institute of Allergy and Infectious Diseases/National Institutes of Health ### 79171###Presenter
1:00 PM - 2:00 PM

Lunch (on your own)
1:00 PM - 2:00 PM

Lunch (on Your Own)

Favorite
2:00 PM - 4:00 PM

Symposium 3: Therapeutic Vaccines for Addiction
2:10 PM - 2:40 PM

S3-1 - Vaccination as a Means to Mitigate Drug Addiction

Favorite

Kim D. Janda, PhD – The Scripps Research Institute ### 307025###Presenter
2:40 PM - 3:10 PM

S3-2 - Development of Vaccines to Prevent and Treat Addiction To Cocaine and Opiate Drugs

Favorite

Thomas R. Kosten, MD – Baylor College of Medicine ### 307026###Presenter
3:10 PM - 3:40 PM

S3-3 - Treating Cocaine Addiction with Viral Vector for Cholinesterase in Mice, Rats, and Rhesus Monkeys

Favorite

William S. Brimijoin, PhD – Mayo Clinic and Foundation ### 307027###Presenter
4:00 PM - 4:30 PM

Coffee Break
4:00 PM - 4:30 PM

Coffee Break

Favorite
4:30 PM - 5:30 PM

Symposium 4: Human Challenge Models in Vaccine Development
4:35 PM - 4:55 PM

S4-1 - Scientific and Regulatory Aspects of Such Studies of Vaccines

Favorite

Wellington Sun, MD – US Food and Drug Administration ### 141569###Presenter
4:55 PM - 5:15 PM

S4-2 - FDA Licensure of a Cholera Vaccine as a Result of Pivotal Efficacy Derived from Human Challenges

Favorite

Wilbur H. Chen, MD, MS – University of Maryland School of Medicine ### 70833###Presenter
5:30 PM - 6:30 PM

Welcome Reception & Poster Presentations
5:30 PM - 6:30 PM

Welcome Reception & Poster Presentations

Favorite
Tuesday, April 25, 2017
7:30 AM - 8:30 AM

Poster Presentations & Continental Breakfast
7:30 AM - 8:30 AM

Poster Presentations & Continental Breakfast

Favorite
8:30 AM - 9:30 AM

D.A. Henderson Tribute: Legacy of Eradication through Vaccines
8:30 AM - 9:30 AM

D.A. Henderson Tribute: Legacy of Eradication Through Vaccines

Favorite

Bill H. Foege, MD, MPH – Emory University ### 307028###Keynote Speaker @@@ Myron M. Levine, MD, D.T.P.H. – University of Maryland School of Medicine ### 142945###Moderator
9:30 AM - 10:00 AM

Coffee Break
9:30 AM - 10:00 AM

Coffee Break

Favorite
10:00 AM - 11:30 AM

Oral Abstracts: Epidemiology and Burden of Disease
10:00 AM - 10:15 AM

OA1-1 - Using the 4 Pillars™ Practice Transformation Program to Increase Adolescent Human Papillomavirus, Meningococcal, and Tetanus-Diphtheria-Pertussis Vaccination

Favorite

Richard K. Zimmerman, MD, MPH, MA, MS – University of Pittsburgh ### 71537###Speaker
10:15 AM - 10:30 AM

OA1-2 - Antibody Responses to Zika Virus in Primary and Secondary Flavivirus Infections

Favorite

Muktha S. Natrajan, PhD, MPH – Emory University ### 324295###Speaker
10:30 AM - 10:45 AM

OA1-3 - Modeling Reveals How Vaccination Could Significantly Reduce Hepatitis C Transmission via Syringe Sharing

Favorite

Marian E. Major, PhD – US Food and Drug Administration ### 324269###Speaker
10:45 AM - 11:00 AM

OA1-4 - Influence of e-Health Text Messages Linked to Health Portal on College Students' Influenza Vaccine Rate

Favorite

Catherine A. Sharbaugh, DNP, CRNP – Haverford College ### 211572###Speaker
11:00 AM - 11:15 AM

OA1-5 - The Global Burden of Lower Respiratory Infections: Results from the Global Burden of Disease Study 2015

Favorite

Chris E. Troeger, MPH – University of Washington ### 324305###Speaker
11:15 AM - 11:30 AM

OA1-6 - The Global Burden of Shigella and Enterotoxigenic E. coli Diarrhea

Favorite

Ibrahim A. Khalil, MD, MPH – University of Washington ### 324306###Speaker
10:00 AM - 11:30 AM

Oral Abstracts: Preclinical and Clinical Trials
10:00 AM - 10:15 AM

OA2-1 - A Non-glycosylated G Protein Vaccine Protects Against Homologous and Heterologous Respiratory Syncytial Virus Challenge in Both Mice and Cotton Rats

Favorite

Surender Khurana, PhD – US Food and Drug Administration ### 71062###Speaker
10:15 AM - 10:30 AM

OA2-2 - “Immune Focused” Influenza Vaccines Provide Better, Long-lasting Cross-protective Immunity Compared to IIV Against Pandemic h5 & h7 Highly Pathogenic Influenza Viruses

Favorite

Surender Khurana, PhD – US Food and Drug Administration ### 71062###Speaker
10:30 AM - 10:45 AM

OA2-3 - Sci-B-Vac, a Third Generation Hepatitis B Vaccines That Elicits Rapid and Robust Seroprotection in Adults

Favorite

Francisco J. Diaz Mitoma, MD, PhD, FRCPC – VBI Vaccines, Inc ### 324256###Speaker
10:45 AM - 11:00 AM

OA2-4 - The IVAX Toolkit: Accelerating and Advancing Human and Animal Vaccine Design in Silico

Favorite

Frances Terry, MPH – EpiVax ### 324314###Speaker
11:00 AM - 11:15 AM

OA2-5 - Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-Acellular Pertussis Vaccine in Mice

Favorite

Yung-Yi C. Mosley, BVM, MS, PhD – Purdue University ### 324225###Speaker
11:15 AM - 11:30 AM

OA2-6 - Immunogenicity, Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Recombinant Vaccine in Healthy Subjects in Vietnam

Favorite

Vu D. Thiem, MD, PhD – National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam ### 324263###Speaker
12:00 PM - 1:00 PM

Awards Luncheon
12:10 PM - 12:30 PM

Robert Austrian Memorial Lecture | Thinking Outside the Bug: An Admiral’s Reflections on the Captain of the Men of Death

Favorite

Anne Schuchat, MD (RADM, USPHS) ### 350869###Lecturer
12:30 PM - 12:40 PM

Dr. Charles Mérieux Award for Achievement in Vaccinology and Immunology

Favorite

Samuel L. Katz, MD – Duke University School of Medicine ### 350874###Award Recipient
12:40 PM - 1:00 PM

Maurice R. Hilleman Early-Stage Career Investigator Award

Favorite

Jourdan A. Andersson, BS – UTMB ### 324457###Award Recipient
1:30 PM - 3:00 PM

Oral Abstracts: New and Emerging Vaccines (Part 1)
1:30 PM - 1:45 PM

OA3-1 - Evolution of HIV-1 Env Open Trimer Conformation Driven by Peptide Fusion Inhibitor Resistance

Favorite

Paul W. Keller, PhD – FDA ### 211825###Speaker
1:45 PM - 2:00 PM

OA3-2 - Effect of Influenza Vaccination on Lymphocyte Mirna Profiles

Favorite

Richard B. Kennedy, PhD – Mayo Clinic and Foundation ### 211620###Speaker
2:00 PM - 2:15 PM

OA3-3 - Identification of Highly Conserved Influenza A HLA-A2 and HLA-DR-restricted T cell Epitopes Capable of Inducing Robust Heterotypic Protective Immunity

Favorite

Daniel F. Hoft, MD, PhD – Saint Louis University ### 70991###Speaker
2:15 PM - 2:30 PM

OA3-4 - Serum Antibody Profiling Following Vaccination with an Adjuvanted Thermostable Subunit Antigen Reveals a Possible Correlate of Immunity to Ricin Toxin

Favorite

Jennifer L. Yates, PhD – Heath Research Inc. ### 324344###Speaker
2:30 PM - 2:45 PM

OA3-5 - Protection of Horse Foals Against the Tuberculosis-like Pathogen Rhodococcus Equi via Conjugate Vaccine (AV0328)-induced Maternal Antibody to Poly-N-acetyl glucosamine

Favorite

Gerald B. Pier, PhD – Brigham & Women's Hospital ### 324328###Speaker
2:45 PM - 3:00 PM

OA3-6 - Viral Vector-based Prime/Boost Regimen to Maximize Tissue-Resident Memory T Cell Responses for Therapeutic Vaccination Against HPV Cervicovaginal Neoplasia

Favorite

Nicolas Cuburu, PhD – National Institutes of Health National Cancer Institute ### 143142###Speaker
1:30 PM - 3:00 PM

Oral Abstracts: Vaccine Safety (Part 1)
1:30 PM - 1:45 PM

OA4-1 - Mapping the Morality of Vaccine Hesitance: Associations of Moral Foundation Values with Vaccine Hesitance

Favorite

Avnika B. Amin – Omer Research Group, Rollins School of Public Health, Emory University ### 324340###Speaker
1:45 PM - 2:00 PM

OA4-2 - Zika in the United States: Transmission and Strategies for Control

Favorite

L. Beryl Guterman, MSPH Candidate 2017 – Rollins School of Public Health Emory University ### 324353###Speaker
2:00 PM - 2:15 PM

OA4-3 - Safety of MenB-FHbp, a Meningococcal Serogroup B Vaccine, in US Young Adults: Results from a Phase 3 Study

Favorite

John L. Perez, MD, MA – Pfizer Vaccine Clinical Research ### 211631###Speaker
2:15 PM - 2:30 PM

OA4-4 - Safety of MenB-FHbp, a Meningococcal Serogroup B Vaccine, in US Adolescents: Results from a Phase 3 Study

Favorite

John L. Perez, MD, MPH – Pfizer Vaccine Clinical Research ### 211629###Speaker
2:30 PM - 2:45 PM

OA4-5 - Genetic Diversity of Nonstructural Asibi/17D Mutant Yellow Fever Viruses

Favorite

Natalie D. Collins, MPH, MLS (ASCP) – University of Texas Medical Branch ### 211696###Speaker
2:45 PM - 3:00 PM

OA4-6 - Tumorigenicity of Spontaneously Immortalized Cells Used in Vaccine Manufacture: Responsiveness to Matrigel^® as a Possible Trait for Tumorigenicity Characterization

Favorite

Haruhiko Murata, MD, PhD – US Food and Drug Administration ### 211717###Speaker
3:00 PM - 3:30 PM

Coffee Break
3:00 PM - 3:30 PM

Coffee Break

Favorite
3:30 PM - 5:00 PM

Oral Abstracts: New and Emerging Vaccines (Part 2)
3:30 PM - 3:45 PM

OA5-1 - Willingness to Pay for an Ebola Vaccine Among a US National Sample During the 2014–2016 West African Ebola Outbreak

Favorite

Julia E. Painter, PhD, MPH – George Mason University ### 324283###Speaker
3:45 PM - 4:00 PM

OA5-2 - Advancing the Clinical Development of GEN-003, a Therapeutic Vaccine for Recurrent Genital Herpes

Favorite

Thomas C. Heineman, MD, PhD – Genocea Biosciences ### 324280###Speaker
4:00 PM - 4:15 PM

OA5-3 - A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity Against Trypanosoma cruzi

Favorite

Nisha J. Garg, PhD, MBA – University of Texas Medical Branch ### 324349###Speaker
4:15 PM - 4:30 PM

OA5-4 - Immune Response and Viral Persistence in Acute Human Zika Virus Infection—a Preliminary Report

Favorite

Lilin Lai, MD – Emory University ### 142998###Speaker
4:30 PM - 4:45 PM

OA5-5 - Tools to Characterize the Immune Response to Zika Virus (ZIKV): Reporter Virus Particles, Anti-ZIKV MAbs, and Antibody Epitope Mapping

Favorite

Edgar Davidson, PhD – Integral Molecular ### 211787###Speaker
4:45 PM - 5:00 PM

OA5-6 - Human Antibody Repertoire Following VSV-Ebola Vaccination Identifies Novel Targets and Virus Neutralizing IgM Antibodies

Favorite

Surender Khurana, PhD – US Food and Drug Administration ### 71062###Speaker
3:30 PM - 5:00 PM

Oral Abstracts: Vaccine Safety (Part 2)
3:30 PM - 3:45 PM

OA6-1 - Nonclinical Investigations into the Reduced Effectiveness of the H1N1pdm09 Component of the Live Attenuated Influenza Vaccine

Favorite

Oliver E. Dibben, PhD – MedImmune ### 324398###Speaker
3:45 PM - 4:00 PM

OA6-2 - Evaluating Infant Mortality and Hospitalizations After Maternal Immunization in the Vaccine Safety Datalink, 2004-2014

Favorite

Lakshmi Sukumaran, MD, MPH – Centers for Disease Control and Prevention ### 324250###Speaker
4:00 PM - 4:15 PM

OA6-3 - Recommended Immunization Schedule and All-cause Mortality

Favorite

Natalie L. McCarthy, MPH – Centers for Disease Control and Prevention ### 143032###Speaker
4:15 PM - 4:30 PM

OA6-4 - Adverse Events Following Quadrivalent Meningococcal CRM-Conjugate Vaccine Reported to the Vaccine Adverse Event Reporting System (VAERS), 2010-2015

Favorite

Tanya R. Myers, PhD, MSc – Emory University / Centers for Disease Control & Prevention ### 324226###Speaker
4:30 PM - 4:45 PM

OA6-5 - Feasibility of Examining Potential Mechanisms for Intussusception Following Rotavirus Vaccination in Infants 6-13 Weeks of Age

Favorite

Mary A. Staat, MD, MPH – Cincinnati Children's Hospital Medical Center ### 324238###Speaker
4:45 PM - 5:00 PM

OA6-6 - Adverse Events Following Purified Chick Embryo Cell (PCEC, Rabavert^®) Vaccine in the Vaccine Adverse Event Reporting System, 2006–2015

Favorite

Pedro L. Moro, MD, MPH – Centers for Disease Control and Prevention ### 79092###Speaker
5:30 PM - 7:00 PM

Hilleman: A Perilous Quest to Save the World's Children
Movie Screening followed by Q&A with Producer, Paul A. Offit, MD
5:30 PM - 7:00 PM

Hilleman: A Perilous Quest to Save the World's Children
Movie Screening followed by Q&A with Paul A. Offit, MD

Favorite

Paul A. Offit, MD – University of Pennsylvania Perelman School of Medicine
Director of the Vaccine Education Center
The Children’s Hospital of Philadelphia ### 318698###Featured Presenter
Wednesday, April 26, 2017
7:00 AM - 7:45 AM

Dr. Richard J. Duma Meet the Experts Breakfast Sessions
7:00 AM - 7:45 AM

Biology of Antibody-Enhanced Dengue Disease: Evidence of Increased Risk After CYDTDV Vaccination

Favorite

Scott B. Halstead, MD – International Vaccine Institute ### 78363###Featured Presenter
7:00 AM - 7:45 AM

Clinical Development of Synthetic DNA Vaccines: Advances in the Technology

Favorite

David B. Weiner, PhD – Wistar Institute ### 307030###Featured Presenter
7:00 AM - 7:45 AM

Development and Approval Pathways for Vaccines to Prevent Emerging Infectious Diseases: FDA Regulatory Perspective

Favorite

Marion F. Gruber, PhD – US Food and Drug Administration ### 78362###Featured Presenter
7:00 AM - 7:45 AM

How to Get Published: Writing Effective Journal Articles

Favorite

Gregory A. Poland, MD – Mayo Clinic and Foundation ### 78369###Featured Presenter
7:00 AM - 7:45 AM

Maximizing Benefit and Minimizing Risk for the World's First Licensed Dengue Vaccine: CYD-TDV

Favorite

Timothy P. Endy, MD, MPH – State University of New York, Upstate Medical University ### 79041###Featured Presenter
7:00 AM - 7:45 AM

Post-licensure Vaccine Safety Monitoring

Favorite

Tom T. Shimabukuro, MD, MPH, MBA – Centers for Disease Control and Prevention ### 142883###Featured Presenter
7:00 AM - 8:00 AM

Continental Breakfast
7:00 AM - 8:00 AM

Continental Breakfast

Favorite
8:00 AM - 10:00 AM

Symposium 5: Vaccine Innovations
8:10 AM - 8:30 AM

S5-1 - Clinical Development of Synthetic DNA Vaccines: Advances in the Technology

Favorite

David B. Weiner, PhD – Wistar Institute ### 307030###Presenter
8:30 AM - 8:50 AM

S5-2 - mRNA-based Vaccines Against HIV and Other Pathogens

Favorite

Drew Weissman, MD, PhD – University of Pennsylvania ### 307032###Presenter
8:50 AM - 9:10 AM

S5-3 - Structure-based Immunogen Design for Flavivirus Vaccines

Favorite

Felix A. Rey, PhD – Institut Pasteur ### 307031###Presenter
9:10 AM - 9:30 AM

S5-4 - Recoding Structural Glycoprotein E2 in Classical Swine Fever Virus (CSFV) and Its Potential Use as a Vaccine Candidate

Favorite

Lauro Velazquez, DVM, MSc – Plum Island Animal Disease Center ### 316812###Presenter
10:00 AM - 10:30 AM

Coffee Break
10:00 AM - 10:30 AM

Coffee Break

Favorite
10:30 AM - 12:30 PM

Symposium 6: Evaluating Vaccine Safety During Public Health Emergencies
10:40 AM - 11:10 AM

S6-1 - Systematic Observational Method for Narcolepsy and Influenza Immunization Assessment (Somnia): Risk of Narcolepsy Following Adjuvanted 2009 H1N1 Influenza Vaccines

Favorite

Tom T. Shimabukuro, MD, MPH, MBA – Centers for Disease Control and Prevention ### 142883###Presenter
11:10 AM - 11:40 AM

S6-2 - Maintaining Public Confidence in Vaccines During a Pandemic

Favorite

Daniel A. Salmon, PhD – Johns Hopkins Bloomberg School of Public Health ### 316814###Presenter
11:40 AM - 12:10 PM

S6-3 - Monitoring Influenza Vaccine Safety in Sentinel/Prism

Favorite

Katherine Yih, PhD, MPH – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute ### 316815###Presenter
12:30 PM - 1:30 PM

Lunch (on your own)
12:30 PM - 1:30 PM

Lunch (on Your Own)

Favorite
1:30 PM - 2:30 PM

Closing Keynote: Vaccines to Fight Emerging Infectious Diseases: Use of Novel Platform Technologies (non-CME)
1:30 PM - 2:30 PM

Closing Keynote: Vaccines to Fight Emerging Infectious Diseases: Use of Novel Platform Technologies (non-CME)

Favorite

Phyllis A. Arthur, MBA – Biotechnology Innovation Organization ### 318682###Moderator @@@ Marc-André D'Aoust, PhD – Medicago ### 367442###Panelist @@@ David B. Weiner, PhD – Wistar Institute ### 307030###Panelist @@@ Jeffrey B. Ulmer, PhD – GSK Vaccines ### 367443###Panelist @@@ Christopher R. Heery, MD – Bavarian Nordic A/S ### 367441###Panelist
2:45 PM - 4:45 PM

Technical Tour to GSK (Pre-Registration Required)
2:45 PM - 4:45 PM

Technical Tour to GSK (Pre-Registration Required)
Location: Offsite

Favorite